Get the Stockscreener App
5.00
0.20%
+0.010
MeiraGTx Holdings plc stock is currently priced at $5.00, with a 24-hour trading volume of 77,268.
It has seen a +0.20% increased in the last 24 hours and a -7.92% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.99 pivot point. If it approaches the $5.06 resistance level, significant changes may occur.
Previous Close:
$4.99
Open:
$5.17
24h Volume:
77,268
Market Cap:
$321.53M
Revenue:
$14.02M
Net Income/Loss:
$-84.03M
P/E Ratio:
-1.9531
EPS:
-2.56
Net Cash Flow:
$-125.54M
1W Performance:
+4.17%
1M Performance:
-7.92%
6M Performance:
-5.66%
1Y Performance:
-14.38%
1D Range:
$4.98
$5.25
52W Range:
$3.49
$8.20
MeiraGTx Holdings plc Stock (MGTX) Company Profile
Name
MeiraGTx Holdings plc
Sector
Industry
Phone
646-490-2965
Address
430 East 29th Street, 10th Floor, New York, NY
MeiraGTx Holdings plc Stock (MGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Sep-15-20 | Resumed | BofA Securities | Buy |
| Sep-03-19 | Initiated | Piper Jaffray | Overweight |
| Feb-27-19 | Reiterated | Chardan Capital Markets | Buy |
| Jul-03-18 | Initiated | Barclays | Overweight |
| Jul-03-18 | Initiated | BofA/Merrill | Buy |
View All
MeiraGTx Holdings plc Stock (MGTX) Latest News
MeiraGTx to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
GlobeNewswire Inc.
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
GlobeNewswire Inc.
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?
Zacks Investment Research
MeiraGTx Holdings plc Stock (MGTX) Financials Data
MeiraGTx Holdings plc (MGTX) Revenue 2024
MGTX reported a revenue (TTM) of $14.02 million for the quarter ending December 31, 2023, a -11.95% decline year-over-year.
MeiraGTx Holdings plc (MGTX) Net Income 2024
MGTX net income (TTM) was -$84.03 million for the quarter ending December 31, 2023, a +35.17% increase year-over-year.
MeiraGTx Holdings plc (MGTX) Cash Flow 2024
MGTX recorded a free cash flow (TTM) of -$125.54 million for the quarter ending December 31, 2023, a -6.33% decrease year-over-year.
MeiraGTx Holdings plc (MGTX) Earnings per Share 2024
MGTX earnings per share (TTM) was -$1.47 for the quarter ending December 31, 2023, a +48.78% growth year-over-year.
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc has a research collaboration and evaluation agreement with Janssen Pharmaceuticals, Inc. the company was founded in 2015 and is based in New York, New York.
1.62%
0.15%
Cap:
|
Volume (24h):